Lupin spins out two oncology assets into new company, takes 82% stake
Lupin's US unit licenses PRMT5 and SOS1 programs to Kaveri Therapeutics for $1.6M in equity, a tiny bet against a ₹1,07,152 cr market cap.
— 8 earlier stories on Lupin Ltd. →What's new
- Lupin US subsidiary licensed two oncology clinical-stage programs to Kaveri Therapeutics.
- Lupin received 332,000 common shares, an 82.2% stake, valued at USD 1.6M.
- Kaveri will raise additional capital; Lupin provides seed funding.
Why this matters
The deal is immaterial to Lupin's financials but signals a strategy to advance early-stage assets through a separate vehicle, limiting risk. Given the small size and early stage, it's a portfolio management move rather than a catalyst.
What we're watching
- Whether Kaveri secures significant external funding.
- Any future data readouts for PRMT5 and SOS1 programs.
- Potential for similar spin-outs of other early-stage assets.
The full read
Lupin has effectively spun out two of its clinical-stage oncology programs into a separate entity, Kaveri Therapeutics, in exchange for an 82.2% equity stake worth just USD 1.6M. The programs, a PRMT5 inhibitor and an SOS1 inhibitor, have shown early promise at ASCO but remain years from commercialization. Lupin's US subsidiary will provide seed funding, and Kaveri will hunt for external capital to fund global trials. For a company with a ₹1,07,152 cr market cap and trailing revenue of ₹27,500 crore, this deal is a rounding error. It won't move the earnings needle. What it does is signal a preference to de-risk early-stage R&D through separate vehicles rather than carry the full cost on its own books.
Questions answered
- What exactly is Lupin doing?
- Lupin licensed its PRMT5 and SOS1 oncology programs to a newly formed company, Kaveri Therapeutics, in exchange for an 82.2% equity stake worth USD 1.6M.
- Why is Lupin doing this?
- To advance the programs through a separate entity that can raise its own capital, limiting Lupin's financial exposure while retaining majority control.
- How big is this deal for Lupin?
- Immaterial — USD 1.6M is negligible compared to Lupin's market cap of ₹1,07,152 cr and annual revenue of ~₹27,500 crore.
- What are the programs?
- LNP7457 (PRMT5 inhibitor) and LNP8701 (SOS1 inhibitor), both targeting solid tumors and having presented positive data at ASCO 2025 and 2026.
- Who will run Kaveri?
- CEO Kristi Jones and CMO Dr. Robert Pierce, focusing on lung, pancreatic, ovarian, and CNS-related cancers.
- Does this change Lupin's near-term earnings?
- No, the transaction is too small to affect earnings; it's a portfolio management move.
Lupin Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on LUPIN →- 21 Jul 2026 · 7:13 AM IST Lupin spins out two oncology assets into new company, takes 82% stake
- 27d ago Lupin's Somerset plant gets FDA's cleanest inspection verdict
- 27d ago Lupin wins wider European label for rare-disease drug NaMuscla
- 41d ago Lupin launches Azilsartan generic in US with 180-day exclusivity
- 50d ago Lupin takes Luforbec to Spain, its third European market